Vertex Pharmaceuticals (VRTX) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $137.9B
- As of Nov 5, 2026
- P/E
- 34.68x
- Trailing twelve months
- P/B
- 6.59x
- Latest reported equity
- P/S
- 10.64x
- Trailing twelve months
- ROE
- 19.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $137.9B
- As of Nov 5, 2026
- P/E
- 34.68x
- Trailing twelve months
- P/B
- 6.59x
- Latest reported equity
- P/S
- 10.64x
- Trailing twelve months
- ROE
- 19.0%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
34.68x
P/B
6.59x
P/S
10.64x
Earnings and dividend metrics▾
Earnings
EPS
$15.65
Earnings per share
BPS
$82.31
Book value per share
ROE
19.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $15.65 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $82.31 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 19.0%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 11.9% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $3.08B+11.9%
$2.77B
Jul–Sep '24
$3.08B
Jul–Sep '25
$3.44B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 3, 2026.
- Earnings per share decreased 39.0% from the same quarter a year earlier.
- Revenue increased 11.9% from the same quarter a year earlier.
- Operating income decreased 39.9% from the same quarter a year earlier.
- Net income decreased 39.6% from the same quarter a year earlier.
Filed Nov 3, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Brennan Daniel J.Director · Oct 20, 2026Grant or award795 shares · $400KAvg. price $503.47795 shares held after
- van Grunsven JasperEVP, CP and NPPO · Sep 8, 2026Grant or award8,682 shares · $0Avg. price $08,682 shares held after
- Ambrose KristenSVP & Chief Accounting Officer · Aug 28, 2026Grant or award5,000 shares · $0Avg. price $011,624 shares held after
- SACHS BRUCE IDirector · Aug 27, 2026Gift6,000 shares · $0Avg. price $039,000 shares held after
- Tatsis OuraniaEVP, Chief Reg. & Quality Off. · Jul 21, 2026Grant or award8,251 shares · $0Avg. price $053,572 shares held after
- Sachdev AmitEVP Chief Patient & Ext Af Off · Jul 21, 2026Grant or award8,251 shares · $0Avg. price $066,512 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QVertex said it acquired Crinetics in September 2026 for $85.00 per share in cash, with a total equity value of $10.0 billion and a net value of $9.0 billion after deducting cash, cash equivalents and marketable securities acquired. The company said it funded the deal with cash on hand and marketable securities, plus $4.5 billion in proceeds from the 2026 Term Loan.Published Nov 3, 2026 · Filed Nov 3, 2026Read the summary →
- AI summary8-KThe company said total revenue for Q3 2026 rose to $3.44 billion, up 12% from Q3 2025. It cited continued performance of cystic fibrosis (CF) therapies and expansion into additional disease areas as the main drivers.Published Nov 2, 2026 · Filed Nov 2, 2026Read the summary →
- AI summary8-KVertex said Daniel Brennan was appointed to its board of directors as a new member on October 20, 2026. As a result, the size of the board was increased from 10 to 11 members.Published Oct 20, 2026 · Filed Oct 20, 2026Read the summary →
- Vertex said it acquired Crinetics in September 2026 for $85.00 per share in cash, with a total equity value of $10.0 billion and a net value of $9.0 billion after deducting cash, cash equivalents and marketable securities acquired. The company said it funded the deal with cash on hand and marketable securities, plus $4.5 billion in proceeds from the 2026 Term Loan.Read the full analysis →
- The company said total revenue for Q3 2026 rose to $3.44 billion, up 12% from Q3 2025. It cited continued performance of cystic fibrosis (CF) therapies and expansion into additional disease areas as the main drivers.Read the full analysis →
- Vertex said Daniel Brennan was appointed to its board of directors as a new member on October 20, 2026. As a result, the size of the board was increased from 10 to 11 members.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Vertex Pharmaceuticals (VRTX) stock information
NASDAQ
Vertex Pharmaceuticals (VRTX) is listed on NASDAQ. Its market capitalization is about $137.9B. On trailing-twelve-month earnings the P/E ratio is 34.68, and the P/B ratio is 6.59. Return on equity is 19%. These figures are computed in-house from official filings and are reference information only.
Vertex Pharmaceuticals — frequently asked questions
- What is the P/E ratio of Vertex Pharmaceuticals (VRTX)?
- On a trailing-twelve-month basis, VRTX trades at a P/E ratio of 34.68. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Vertex Pharmaceuticals?
- VRTX has a market capitalization of about $137.9B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.